Alkem Laboratories Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Alkem Laboratories kazanç ve gelirin sırasıyla yıllık 10.6% ve 9.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 10.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.6%

Kazanç büyüme oranı

10.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.6%
Gelir büyüme oranı	9.4%
Gelecekteki özkaynak getirisi	18.6%
Analist kapsamı	Good
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17

Kazanç ve Gelir Büyüme Tahminleri

NSEI:ALKEM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	161,346	27,516	19,790	23,269	19
3/31/2026	147,401	25,256	16,921	21,124	22
3/31/2025	133,577	22,434	15,906	23,794	22
9/30/2024	128,319	21,223	15,054	19,549	N/A
6/30/2024	127,317	20,542	N/A	N/A	N/A
3/31/2024	126,676	17,958	16,888	19,481	N/A
12/31/2023	126,344	15,732	N/A	N/A	N/A
9/30/2023	123,514	14,329	18,370	20,537	N/A
6/30/2023	119,906	11,433	N/A	N/A	N/A
3/31/2023	115,993	9,842	14,496	16,825	N/A
12/31/2022	111,805	10,208	N/A	N/A	N/A
9/30/2022	107,586	10,917	5,527	8,426	N/A
6/30/2022	104,792	13,051	N/A	N/A	N/A
3/31/2022	106,342	16,456	7,721	11,110	N/A
12/31/2021	103,425	17,780	N/A	N/A	N/A
9/30/2021	100,416	17,033	10,478	13,213	N/A
6/30/2021	96,044	16,311	N/A	N/A	N/A
3/31/2021	88,650	15,850	11,051	12,649	N/A
12/31/2020	87,218	15,338	N/A	N/A	N/A
9/30/2020	85,971	14,648	8,916	11,455	N/A
6/30/2020	84,984	13,636	N/A	N/A	N/A
3/31/2020	83,444	11,271	2,220	5,851	N/A
12/31/2019	81,484	11,057	N/A	N/A	N/A
9/30/2019	78,929	9,262	5,173	8,756	N/A
6/30/2019	75,478	8,098	N/A	N/A	N/A
3/31/2019	73,572	7,605	2,505	7,797	N/A
12/31/2018	70,157	6,602	N/A	N/A	N/A
9/30/2018	68,318	6,293	N/A	N/A	N/A
6/30/2018	67,788	6,955	N/A	N/A	N/A
3/31/2018	63,918	6,309	N/A	2,660	N/A
12/31/2017	60,044	7,009	N/A	N/A	N/A
9/30/2017	57,285	7,626	N/A	N/A	N/A
6/30/2017	55,019	7,248	N/A	N/A	N/A
3/31/2017	56,875	8,920	N/A	4,711	N/A
12/31/2016	56,933	7,732	N/A	N/A	N/A
9/30/2016	54,992	7,267	N/A	N/A	N/A
6/30/2016	52,419	7,108	N/A	N/A	N/A
3/31/2016	49,248	7,416	N/A	7,258	N/A
12/31/2015	47,975	8,189	N/A	N/A	N/A
9/30/2015	44,556	7,227	N/A	4,023	N/A
6/30/2015	40,459	5,781	N/A	N/A	N/A
3/31/2015	37,434	3,916	N/A	3,255	N/A
3/31/2014	31,191	4,353	N/A	2,900	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ALKEM 'nin tahmini kazanç büyümesi (yıllık 10.6% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: ALKEM şirketinin kazançlarının (yıllık 10.6% ) Indian pazarından (yıllık 18.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: ALKEM şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: ALKEM şirketinin gelirinin (yıllık 9.4% ) Indian pazarından (yıllık 10.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ALKEM şirketinin gelirinin (yıllık 9.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ALKEM 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/31 12:01
Gün Sonu Hisse Fiyatı	2024/12/31 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Alkem Laboratories Limited 35 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Prashant Nair	Ambit Capital
Shrikant Akolkar	Angel Broking Private Limited
null null	Antique Stockbroking Ltd.

Alkem Laboratories Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alkem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings: EPS and revenues miss analyst expectations

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited Announces Change in Management

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Less than half of directors are independent

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Final dividend of ₹5.00 announced

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024

Full year 2024 earnings released: EPS: ₹150 (vs ₹82.31 in FY 2023)

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa

Alkem Laboratories Limited Appoints Srinivas Singh as (Executive) Additional Director and Whole Time Director

Alkem Laboratories Limited Announces Retirement of Balmiki Prasad Singh as Executive Director